Friday, November 10, 2017 11:23:10 AM
Game7, this was the price point where I first started investing in Opko back in early to mid 2012. WOW, the company has come so far with products and trials and yet here it sits at 5 years of dead money. I didnt listen to the CC yesterday but guessing by your reaction it was more of the same ol' same ol'. Out of curiosity did Kevin Degeeter at Thalmann ask anymore questions in the Q and A. Did they even have a Q and A lol?
One unique thing about Opko is that Frost has controlled all the investment Opko by-passing outside investors. He always had his "group" there when the company needed money. This may be one of the reasons that the stock has yet to gain traction. The big boys ALWAYS get their shares one way or another. When you go around them (no ipo's or secondaries) , they make you pay.
Kind of ironic that Frost hasnt bought and the pps gets hammered.
jmho
Tred
One unique thing about Opko is that Frost has controlled all the investment Opko by-passing outside investors. He always had his "group" there when the company needed money. This may be one of the reasons that the stock has yet to gain traction. The big boys ALWAYS get their shares one way or another. When you go around them (no ipo's or secondaries) , they make you pay.
Kind of ironic that Frost hasnt bought and the pps gets hammered.
jmho
Tred
Recent OPK News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/15/2026 08:38:03 PM
- OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies • GlobeNewswire Inc. • 05/12/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/30/2026 08:04:06 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 08:01:43 PM
- OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China • GlobeNewswire Inc. • 04/30/2026 12:30:00 PM
- BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform • GlobeNewswire Inc. • 04/30/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 08:06:14 PM
- OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results • GlobeNewswire Inc. • 04/28/2026 08:05:00 PM
- OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas • GlobeNewswire Inc. • 04/22/2026 12:00:00 PM
- OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026 • GlobeNewswire Inc. • 04/21/2026 08:05:00 PM
- OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19 • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:25:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:16:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 08:50:09 PM
- OPKO Health to Participate in the Jefferies Biotech on the Beach Summit • GlobeNewswire Inc. • 02/27/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 09:07:43 PM
- OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results • GlobeNewswire Inc. • 02/26/2026 09:05:00 PM
- OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 • GlobeNewswire Inc. • 02/12/2026 01:00:00 PM
- OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism • GlobeNewswire Inc. • 02/04/2026 01:00:00 PM
- OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/06/2026 09:11:42 PM
- OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference • GlobeNewswire Inc. • 11/19/2025 09:05:00 PM
- NextPlat Reports Third Quarter 2025 Results • PR Newswire (US) • 11/13/2025 01:03:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/29/2025 08:12:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/29/2025 08:11:05 PM
